Revenue Performance - Refractive surgery services accounted for approximately 56.7% of total revenue for the year ended March 31, 2024, with SMILE surgery, LASIK, multifocal intraocular lens replacement, and implantable contact lens procedures included in this category[10]. - Revenue from implantable contact lens procedures increased from approximately HKD 7.2 million for the year ended March 31, 2023, to approximately HKD 21.8 million for the year ended March 31, 2024[11]. - Revenue from other eye treatment services decreased by approximately HKD 2.7 million or 4.6%, from approximately HKD 58.4 million for the year ended March 31, 2023, to approximately HKD 55.7 million for the year ended March 31, 2024[12]. - Revenue from diagnosis and examination services increased by approximately HKD 1.4 million or 13.6%, from approximately HKD 10.3 million for the year ended March 31, 2023, to approximately HKD 11.7 million for the year ended March 31, 2024[12]. - Revenue from the sale of prescription drugs and others increased from approximately HKD 7.3 million for the year ended March 31, 2023, to approximately HKD 7.7 million for the year ended March 31, 2024, representing about 3.4% and 4.0% of total revenue respectively[13]. - Revenue from refractive surgery decreased by approximately HKD 29.5 million or 21.4% from about HKD 137.8 million for the year ended March 31, 2023, to about HKD 108.3 million for the year ending March 31, 2024[23]. - Revenue from SMILE surgery dropped from approximately HKD 87.5 million for the year ended March 31, 2023, to about HKD 56.5 million for the year ending March 31, 2024, due to increased market competition[23]. - The company reported a loss of approximately HKD 75.8 million for the fiscal year ending March 31, 2024, compared to a loss of HKD 3.2 million for the previous year[60]. - The company's revenue for the fiscal year ended March 31, 2024, was HKD 190,933,000, a decrease of 10.7% compared to HKD 213,847,000 in the previous year[130]. - The revenue from children's myopia prevention and control was HKD 7,416,000, a new addition to the revenue streams[155]. Expenses and Financial Performance - Employee benefit expenses increased from approximately HKD 52.6 million for the year ended March 31, 2023, to approximately HKD 61.1 million for the year ended March 31, 2024, representing about 24.6% and 32.0% of total revenue respectively[16]. - Other expenses increased from approximately HKD 31.8 million for the year ended March 31, 2023, to approximately HKD 35.6 million for the year ended March 31, 2024, representing about 14.9% and 18.6% of total revenue respectively[20]. - The company recorded a pre-tax loss of approximately HKD 2.9 million for the year ended March 31, 2023, with a tax expense of about HKD 274,000 due to non-deductible expenses[36]. - The company recognized an impairment loss of approximately HKD 30.0 million related to property, plant, and equipment, and right-of-use assets for the fiscal year 2024, compared to no such loss in the fiscal year 2023[138]. - The company reported a significant depreciation expense of approximately HKD 15.9 million for property and equipment and HKD 21.5 million for right-of-use assets during the fiscal year[97]. - The company incurred impairment losses of approximately HKD 18.3 million for property, plant, and equipment, and HKD 11.7 million for right-of-use assets, recognized in the comprehensive income statement for the fiscal year ending March 31, 2024[53]. - The company recorded a tax credit of approximately HKD 6.1 million for the fiscal year ending March 31, 2024, resulting from a pre-tax loss of approximately HKD 81.9 million[59]. - Adjusted net loss for the year was HKD (45,744,000), an increase of 1,333.5% compared to HKD (3,191,000) in the previous year[130]. Strategic Initiatives and Market Position - The company plans to acquire equity interests in ophthalmology clinics, outpatient departments, or hospitals in China to expand its "Clear" brand business in the region[47]. - The company plans to identify suitable partners for collaboration and expansion to achieve sustainable growth and strengthen its position in the ophthalmic services market[93]. - The company plans to focus on cost-saving measures while maintaining service quality to drive sustainable growth and long-term returns for shareholders[148]. - The company aims to enhance shareholder value through strategic partnerships and market expansion initiatives[93]. - The company is dedicated to the long-term potential of its new business in children's myopia prevention despite the current financial challenges[147]. - The company is exploring innovative strategies to enhance its value proposition and diversify revenue sources while ensuring cost-effectiveness[153]. - The company plans to utilize the net proceeds of approximately HKD 181.9 million from its IPO for future projects as outlined in the prospectus[157]. Operational Changes and Challenges - The company identified two underperforming medical centers, one focused on children's myopia control, which has been operating at a loss since its establishment[19]. - The new medical center established in Tsim Sha Tsui in July 2023 has been operating at a loss since its inception, impacting the company's financial performance[147]. - The company is facing increased competition in the refractive surgery market, particularly with the SMILE procedure, leading to a more price-sensitive market[137]. - The local economic downturn and inflation have significantly affected consumer sentiment and spending, impacting the company's operations[146]. - To enhance operational efficiency, the company plans to relocate its Central Medical Center from 9 Queen's Road to New World Tower, with completion expected in the second half of 2024[134]. Management and Governance - The group has a strong management team with members holding significant positions in various listed companies, enhancing its strategic planning capabilities[81][83][86]. - The financial director, Mr. He Jian, has over 16 years of experience in auditing, financing, and internal control, ensuring robust financial reporting and planning for the group[90]. - The management team emphasizes the importance of independent oversight, with Mr. Li Hengjian serving as the chairman of the audit committee[87]. - The group is committed to maintaining high standards of corporate governance, as evidenced by the diverse backgrounds of its board members[88]. - The board has terminated the pre-IPO share option scheme to better allocate resources and has adopted a new share incentive plan[162]. Cash Flow and Capital Structure - As of March 31, 2024, the company maintained a net cash position with cash and cash equivalents amounting to HKD 141.4 million, down from HKD 207.5 million as of March 31, 2023[94]. - The net cash outflow from investing activities was approximately HKD 26.6 million for the fiscal year ending March 31, 2024, compared to an outflow of HKD 143.8 million in the previous year[74]. - The current ratio as of March 31, 2024, was 4.4 times, down from 5.8 times as of March 31, 2023[72]. - The asset-to-equity ratio is not applicable as the company is in a net cash position as of March 31, 2024[95]. - The company's capital structure is monitored based on the asset-to-liability ratio, which is calculated as net debt divided by total equity[94].

Financial Performance - Revenue for the year ended March 31, 2024, was HKD 190,933,000, a decrease of 10.7% compared to HKD 213,847,000 in the previous year[2] - The net loss for the year was HKD 75,793,000, representing a significant increase of 2,275.2% from HKD 3,191,000 in the prior year[3] - Adjusted net loss for the year was HKD 45,744,000, up 1,333.5% from HKD 3,191,000 in the previous year[2] - Operating loss for the year was HKD 79,872,000, compared to an operating loss of HKD 1,392,000 in the previous year[3] - The company reported a basic and diluted loss per share of HKD 14.4, compared to HKD 0.6 in the previous year[3] - The group recorded a loss of approximately HKD 75.8 million for the year ending March 31, 2024, compared to a loss of HKD 3.2 million for the previous year[60] Revenue Breakdown - Ophthalmic service revenue decreased to HKD 179,070,000 from HKD 206,519,000, representing a decline of 13.3%[13] - Revenue from refractive surgery, the largest source of income, decreased from approximately HKD 137.8 million to about HKD 108.3 million, a decline of 21.4%[38] - Revenue from implantable contact lens procedures increased significantly from approximately HKD 7.2 million to about HKD 21.8 million[38] - Revenue from other eye treatments decreased from approximately HKD 58.4 million to HKD 55.7 million, a decline of 4.6%[39] - Revenue from diagnostic and examination services increased by 13.6% from approximately HKD 10.3 million to about HKD 11.7 million[40] - Sales of prescription drugs and other products rose from approximately HKD 7.3 million to HKD 7.7 million, accounting for 4.0% of total revenue[42] - The company launched a new myopia control service for children, generating approximately HKD 3.2 million in diagnostic services and HKD 4.2 million in sales of vision products[43] Assets and Liabilities - Total assets decreased to HKD 197,830,000 from HKD 287,060,000 year-over-year[4] - Cash and cash equivalents decreased to HKD 141,431,000 from HKD 207,496,000 in the previous year[4] - Non-current assets decreased to HKD 66,955,000 from HKD 93,597,000 year-over-year[4] - The total equity attributable to owners of the company decreased to HKD 189,522,000 from HKD 259,284,000[5] - Trade receivables increased to HKD 2,647,000 from HKD 1,960,000, reflecting a rise of 35%[23] - Trade payables decreased to HKD 4,767,000 from HKD 7,166,000, a reduction of 33%[27] Expenses - Employee benefit expenses increased from approximately HKD 52.6 million in 2023 to HKD 61.1 million in 2024, representing 24.6% and 32.0% of revenue, respectively, due to an increase in average employee count from 110 to 123[48] - Depreciation of property and equipment rose significantly from approximately HKD 6.2 million in 2023 to HKD 15.9 million in 2024, accounting for 2.9% and 8.3% of revenue, respectively, due to the operation of a new medical center[50] - Depreciation of right-of-use assets increased from approximately HKD 18.7 million in 2023 to HKD 21.5 million in 2024, representing 8.7% and 11.3% of revenue, respectively, due to the impact of additional leased properties[51] - Other expenses increased from approximately HKD 31.8 million in 2023 to HKD 35.6 million in 2024, accounting for 14.9% and 18.6% of revenue, respectively[54] Cash Flow - The net cash used in operating activities for the year ended March 31, 2024, was HKD 15.6 million, compared to HKD 16.2 million for the year ended March 31, 2023, primarily due to a pre-tax loss of approximately HKD 81.9 million[80] - The company recorded a net cash inflow from investing activities of HKD 26.6 million for the year ended March 31, 2024, a significant decrease from a net cash outflow of approximately HKD 143.8 million for the previous year[80] - The net cash used in financing activities was HKD 24.1 million for the year ended March 31, 2024, compared to HKD 9.2 million for the year ended March 31, 2023, mainly due to lease payments[81] Strategic Initiatives - The company aims to diversify revenue sources and explore innovative strategies to enhance its value proposition amidst increasing competition in the market[29] - The company plans to acquire equity interests in ophthalmology clinics and hospitals in China to expand its "Clear" brand business[79] - The company aims to establish two new medical centers in Hong Kong to provide ophthalmic services, utilizing approximately 44.8% of the net proceeds from its IPO[89] - The company plans to explore new growth opportunities, including developing myopia prevention services for children[79] IPO and Financial Position - The net proceeds from the initial public offering (IPO) amounted to approximately HKD 181.9 million, which is lower than the estimated net proceeds of HKD 245.6 million disclosed in the prospectus, resulting in a difference of HKD 63.7 million[90] - The board has extended the expected timeline for utilizing the unallocated net proceeds until March 31, 2024, due to operational challenges and uncertainties regarding acquisition opportunities in the Greater Bay Area and potential partners in China[91] - The board believes that the extension of the timeline for utilizing the unallocated net proceeds will not have any significant adverse impact on the group's existing business and operations[91] Governance and Compliance - The audit committee, composed of three independent non-executive directors, reviews the accounting principles and practices adopted by the group and discusses risk management and financial reporting matters[92] - Ernst & Young has confirmed that the financial figures in the preliminary announcement align with the group's consolidated financial statements for the year ending March 31, 2024[93] - The board does not recommend the payment of a final dividend for the year ending March 31, 2024, consistent with the previous year[97] - The annual general meeting is scheduled for August 30, 2024, with a suspension of share transfer registration from August 27 to August 30, 2024, to facilitate voting rights[98]

Financial Performance - For the six months ended September 30, 2023, the company's revenue was approximately HKD 101.6 million, a decrease of about HKD 6.1 million or 5.6% compared to HKD 107.7 million for the same period in 2022[5]. - The company reported a loss of HKD 20.0 million for the six-month period, compared to a profit of HKD 7.9 million in the previous year, indicating a significant decline in profitability[5]. - The company recorded a loss of approximately HKD 20.0 million for the six months ended September 30, 2023, a decrease of HKD 27.9 million compared to a profit of HKD 7.9 million in the same period of 2022[56]. - For the six months ended September 30, 2023, the company reported a loss attributable to owners of HKD 20,019,000, compared to a profit of HKD 7,912,000 for the same period in 2022[155]. Revenue Breakdown - Revenue from refractive surgery decreased by HKD 13.1 million, accounting for 57.1% of total revenue, down from 66.0% in the previous year[21]. - The revenue from SMILE surgery dropped by HKD 15.8 million, representing 30.5% of total revenue, compared to 43.4% in the prior year[21]. - Total revenue from refractive treatments decreased by approximately HKD 13.1 million or 18.4% to about HKD 58.0 million, attributed to economic downturn and increased competition[31]. - Revenue from other eye problem treatments increased by approximately HKD 2.2 million or 7.9% to about HKD 30.1 million, accounting for 29.6% of total revenue[32]. - Revenue from diagnosis and examination services rose by approximately HKD 0.9 million or 17.3% to about HKD 6.1 million, due to an increase in standard fees[32]. - Revenue from multifocal intraocular lens replacement and implantable contact lens procedures increased by approximately HKD 3.4 million or 15.2% to about HKD 25.8 million, driven by an increase in the number of procedures[25]. - The company has introduced a new service for children's myopia prevention, generating HKD 3.1 million in revenue during the reporting period[21]. Operating Expenses - Operating expenses have increased due to the expansion and opening of the new center, but the company remains committed to maintaining financial discipline and optimizing its cost structure[9]. - Employee benefits expenses increased from approximately HKD 23.7 million to HKD 29.2 million, representing 28.7% of total revenue, due to the opening of a new center[28]. - Consultant fees increased from approximately HKD 31.1 million to HKD 41.1 million, accounting for 40.5% of total revenue, due to the expansion of the medical team[35]. - Business development expenses surged from approximately HKD 3.5 million in 2022 to HKD 8.9 million in 2023, primarily due to promotional efforts for the new Tsim Sha Tsui center[37]. - The company incurred share-based payment expenses of HKD 1,987,000 for the six months ended September 30, 2023, compared to none in the previous year[111]. Cash Flow and Liquidity - As of September 30, 2023, the company had cash and cash equivalents of HKD 160.8 million, down from HKD 207.5 million as of March 31, 2023[64]. - The net cash flow from operating activities for the six months ended September 30, 2023, was HKD 7.6 million, compared to HKD 17.7 million for the same period in 2022[84]. - The net cash flow from operating activities was a negative HKD 7,639,000, compared to a positive HKD 17,707,000 in the same period of 2022, representing a decline of approximately 143.2%[94]. - The net cash flow used in investing activities was HKD 34,329,000 for the six months ended September 30, 2023, significantly lower than HKD 205,410,000 in the prior year, indicating a reduction of about 83.3%[94]. - The cash flow from financing activities was a net outflow of HKD 11,871,000 for the current period, contrasting sharply with a net inflow of HKD 67,000 in the same period last year[94]. Capital Expenditures and Investments - Capital expenditures increased significantly from approximately HKD 3.0 million in 2022 to HKD 36.0 million in 2023, primarily for purchasing equipment and renovating leased properties[57]. - The company plans to acquire equity interests in ophthalmology clinics, outpatient departments, or hospitals in China to expand its "Clear" brand business[63]. - The company plans to acquire interests in ophthalmology-related businesses to achieve sustainable growth and strengthen its market position[81]. - The company has contracted but unrecognized capital expenditures of approximately HKD 1.3 million as of September 30, 2023, primarily for the establishment of new centers[75]. Market Outlook and Growth Strategy - The company has identified long-term growth drivers such as an aging population and increased use of electronic devices, which are expected to sustain demand for private ophthalmic services[8]. - The overall market environment remains challenging, but the company is optimistic about the long-term prospects of the industry[8]. - The company aims to achieve sustainable growth through careful expense management and efficiency measures while providing excellent ophthalmic medical services[9]. Shareholder Information - The company does not recommend the payment of an interim dividend for the six months ended September 30, 2023[79]. - The company plans to issue reward shares to executives, with a total of 3,100,000 shares held by trustees under the share reward plan, representing approximately 0.6% of the total issued share capital[110]. - The group reported a diluted earnings per share of HKD 1.5 for the six months ended September 30, 2023, based on a weighted average number of ordinary shares of 524,542,574[132]. Compliance and Governance - The company confirmed compliance with the standard code of conduct for directors during the interim period of 2023[177]. - The board's audit committee consists of three independent non-executive directors, ensuring governance and oversight[178].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清 晰 醫 療 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1406） 截至二零二三年九月三十日止六個月 中期業績 財務摘要 截至九月三十日止六個月 二零二三年 二零二二年 千港元 千港元 變動 收益 101,610 107,691 (5.6%) 期內（虧損）╱溢利 (20,019) 7,912 不適用 純利率(%) 不適用 7.3% 不適用 ...

Financial Performance - As of March 31, 2023, the company had cash and cash equivalents of HKD 207.5 million, down from HKD 241.3 million in 2022[30]. - The total revenue for the year ended March 31, 2023, was approximately HKD 213.8 million, a decrease of about HKD 11.4 million or 5.1% compared to HKD 225.2 million for the year ended March 31, 2022[176]. - For the fiscal year ending March 31, 2023, the company recorded a loss of approximately HKD 3.2 million, compared to a profit of HKD 13.5 million for the previous year[138]. - Cash generated from operating activities for the year ended March 31, 2023, was HKD 16.2 million, a decrease from HKD 27.6 million in the previous year, primarily due to a pre-tax loss of approximately HKD 2.9 million[107]. - The company reported a net loss of HKD 3,191 thousand for the year ended March 31, 2023, compared to a profit of HKD 13,491 thousand in the previous year[168]. Waste Management and Environmental Sustainability - The group generated 173.9 kg of medical waste during the reporting period, with a density of 0.00081 kg per thousand dollars of revenue[31]. - The total hazardous waste produced was 120.0 kg, with a density of 0.00056 kg per thousand dollars of revenue, meeting the established target[31]. - The overall density of hazardous waste was 0.00137 kg per thousand dollars of revenue, slightly deviating from the previous target due to the introduction of chemical waste[31]. - The company emphasizes the importance of proper packaging for medical waste to prevent leakage and ensure safety during handling[32]. - The company is committed to environmental sustainability and has implemented energy-saving measures to optimize resource usage[62]. Risk Management - The company’s board is responsible for evaluating and determining the nature and extent of risks it is willing to take to achieve its strategic objectives[8]. - The company has adopted multiple risk management procedures and guidelines to define implementation authority for key business processes and office functions[9]. - The company has identified potential climate-related risks, including acute risks like extreme weather and chronic risks such as sustained high temperatures, which could lead to business and supply chain disruptions, resulting in decreased revenue[87]. Employee and Labor Relations - The total number of employees as of March 31, 2023, is 136, with a gender breakdown of 114 males and 22 females[93]. - The employee turnover rate in Hong Kong is 44%, with a significantly higher turnover rate of 108% for employees aged 50 and above[94][95]. - The company is committed to complying with all relevant labor laws and regulations, ensuring a diverse and inclusive work environment[89]. - Employee benefits expenses for the year ended March 31, 2023, were approximately HKD 52.6 million, accounting for 24.6% of revenue, up from HKD 42.0 million or 18.7% in the previous year[104]. Business Development and Expansion - The group plans to acquire equity interests in ophthalmology clinics and hospitals in China to expand its "Clear" brand business[127]. - The company is exploring opportunities for mergers and acquisitions and partnerships in the Greater Bay Area to expand its market presence[149]. - The establishment of new medical centers is expected to strengthen the company's service network and consolidate its leadership position in the Hong Kong ophthalmology industry[176]. Financial Position and Liquidity - As of March 31, 2023, the net current assets were HKD 193.5 million, down from HKD 225.4 million as of March 31, 2022[107]. - The group maintained a cash balance to manage financial obligations, indicating no significant liquidity risk[121]. - As of March 31, 2023, the current ratio was 5.8 times, down from 10.3 times as of March 31, 2022, reflecting a decrease in liquidity[130]. - The group has maintained a net cash position as of March 31, 2023, with no outstanding bank loans or borrowings[130]. Revenue Breakdown - The average revenue from refractive surgery services accounted for approximately 64.4% of total revenue for the year ended March 31, 2023[158]. - Revenue from SMILE surgery was HKD 3,944 thousand, representing 77.5% of total revenue, an increase from 72.7% in the previous year[157]. - Revenue from refractive surgery decreased by approximately HKD 14.8 million or 9.7% to about HKD 137.8 million for the year ended March 31, 2023, primarily due to a decline in multifocal intraocular lens replacement surgery revenue[196]. - Revenue from other eye treatments increased by approximately HKD 3.3 million or 6.0% to about HKD 58.4 million for the year ended March 31, 2023, accounting for 27.4% of total revenue[196]. Professional Fees and Expenses - Professional fees increased by approximately HKD 4.2 million or 381.8%, from about HKD 1.1 million for the year ended March 31, 2022, to about HKD 5.3 million for the year ended March 31, 2023[105]. - Other expenses increased from approximately HKD 24.2 million in 2022 to HKD 31.8 million in 2023, accounting for 10.7% and 14.9% of revenue respectively[186]. - Business development expenses rose by approximately HKD 1.5 million or 25.0% from about HKD 6.0 million in 2022 to about HKD 7.5 million in 2023[187].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CLARITY MEDICAL GROUP HOLDING LIMITED 清 晰 醫 療 集 團 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1406） (I)截至二零二三年三月三十一日止年度全年業績；及 (II)終止購股權計劃 (I) 截至二零二三年三月三十一日止年度全年業績 財務摘要 截至三月三十一日止年度 二零二三年 二零二二年 千港元 千港元 變動 收益 213,847 225,237 (5.1%) 年內（虧損）╱溢利 (3,191) 13,491 不適用 年內經調整（虧損）╱溢利淨額(1)及(2) (3,191) 30,885 不適用 ...

Financial Performance - Revenue for the six months ended September 30, 2022, was approximately HKD 107.7 million, a decrease of 8.4% from HKD 117.5 million for the same period in 2021[10]. - Profit for the period was HKD 7.9 million, down 24.5% from HKD 10.5 million in the previous year[10]. - Adjusted net profit decreased by 59.9% to HKD 7.9 million from HKD 19.7 million year-on-year[10]. - The adjusted net profit margin was 7.3%, compared to 16.8% in the previous year[10]. - Total revenue for the period was HKD 107.7 million, down from HKD 117.5 million, reflecting a decrease of HKD 9.8 million[20]. - Operating profit for the same period was HKD 10.6 million, down 27.5% from HKD 14.7 million in the previous year[72]. - Net profit for the six months ended September 30, 2022, decreased to approximately HKD 7.9 million, a decline of 24.8% from HKD 10.5 million in the same period of 2021, with a net profit margin dropping from 8.9% to 7.3%[46]. - For the six months ended September 30, 2022, the profit attributable to the company's owners was HKD 7,912,000, a decrease of 24.5% compared to HKD 10,482,000 for the same period in 2021[112]. - The basic earnings per share for the six months ended September 30, 2022, was HKD 0.015, down from HKD 0.028 in the previous year, reflecting a decline of 46.4%[112]. Revenue Breakdown - Revenue from refractive surgery was approximately HKD 71.1 million, accounting for 66.0% of total revenue, a decrease of HKD 6.1 million or 7.9% from HKD 77.2 million in the same period last year[25]. - Revenue from SMILE surgeries rose by approximately HKD 4.9 million or 11.7% to HKD 46.8 million, driven by the increase in the number of procedures[27]. - Revenue from multifocal intraocular lens replacement decreased by approximately HKD 11.3 million or 33.5% to HKD 22.4 million due to a reduction in the number of procedures performed[27]. - Revenue from other eye treatments was approximately HKD 27.9 million, a decrease of HKD 2.8 million or 9.1% from HKD 30.7 million in the previous year[28]. - Revenue from diagnostic and examination services decreased by approximately HKD 0.4 million or 7.1% to HKD 5.2 million, attributed to a decline in patient visits[29]. - Revenue from the sale of prescription drugs and others was approximately HKD 3.5 million, a decrease from HKD 4.0 million, accounting for 3.3% of total revenue[30]. - Ophthalmology service revenue was HKD 104,169 thousand, down 8.3% from HKD 113,538 thousand year-on-year[100]. Operational Developments - The company signed a non-binding memorandum of understanding with Ren Ai Hospital for collaboration in ophthalmic and medical auxiliary services in Hong Kong[15]. - A three-year lease agreement was signed to expand the existing medical center in Mong Kok, increasing the total floor area to approximately 5,966 square feet, expected to commence operations by the end of this year[16]. - A new medical center in Tsim Sha Tsui is planned, with a total floor area of approximately 13,674 square feet, expected to start operations in the first or second quarter of 2023[16]. - The total floor area of the company's medical centers will increase from approximately 16,936 square feet to about 36,576 square feet following the expansions[16]. - The company aims to strengthen its service network and consolidate its leadership position in the ophthalmic industry in Hong Kong through these expansions[16]. - The company plans to expand its market presence in Hong Kong by establishing new medical centers and through acquisitions[62]. - Future plans include acquiring equity interests in ophthalmology clinics and hospitals in China to expand the "Clear" brand business[62]. Cost and Expenses - For the six months ended September 30, 2022, the cost of used inventory was approximately HKD 19.4 million, accounting for 18.0% of revenue, compared to HKD 19.0 million and 16.1% in the same period of 2021[34]. - Consultant fees for the six months ended September 30, 2022, were approximately HKD 31.1 million, representing 28.9% of total revenue, slightly up from HKD 32.9 million and 28.0% in the prior year[35]. - Employee benefit expenses increased to approximately HKD 23.7 million for the six months ended September 30, 2022, accounting for 22.0% of revenue, up from HKD 19.2 million and 16.3% in 2021, due to increased salaries and headcount[36]. - Depreciation of right-of-use assets was approximately HKD 7.3 million for the six months ended September 30, 2022, accounting for 6.8% of revenue, compared to HKD 7.8 million and 6.6% in the previous year[37]. - Other expenses rose to approximately HKD 15.8 million for the six months ended September 30, 2022, representing 14.7% of revenue, up from HKD 11.8 million and 10.0% in 2021[40]. Cash Flow and Financial Position - Net cash position maintained as of September 30, 2022, with cash and cash equivalents totaling HKD 233.6 million, compared to HKD 241.3 million as of March 31, 2022[65]. - The company reported a decrease in cash generated from operating activities to HKD 17.7 million for the six months ended September 30, 2022, down from HKD 25.4 million in the previous year[66]. - Cash used in investing activities for the six months ended September 30, 2022, was HKD 205.4 million, significantly higher than HKD 0.2 million for the same period in 2021[68]. - The current ratio as of September 30, 2022, was 7.7 times, down from 10.3 times as of March 31, 2022[65]. - Total non-current assets increased to HKD 68,593,000 as of September 30, 2022, compared to HKD 40,552,000 as of March 31, 2022, representing a growth of 68.9%[74]. - Current assets totaled HKD 256,295,000 as of September 30, 2022, up from HKD 249,592,000 as of March 31, 2022, indicating a 2.8% increase[74]. - Total liabilities increased to HKD 54,652,000 as of September 30, 2022, compared to HKD 34,693,000 as of March 31, 2022, marking a rise of 57.5%[74]. - The company's total equity reached HKD 270,236,000 as of September 30, 2022, compared to HKD 255,451,000 as of March 31, 2022, showing an increase of 5.8%[77]. - Cash and cash equivalents decreased to HKD 53,634,000 as of September 30, 2022, from HKD 64,754,000 as of September 30, 2021, a decline of 17.2%[85]. Shareholder Information - The company issued 125,000,000 shares at an issue price of HKD 1.6 per share, raising a total of HKD 200,000,000 before expenses during the share offering completed on February 18, 2022[89]. - The total number of shares held by directors and key executives as of September 30, 2022, included 107,505,880 shares, representing approximately 20.61% of the company's equity[161]. - Clear Lead Ventures Limited holds 165,775,126 shares, representing approximately 31.77% of the total shares[169]. - Ultimate Bliss Limited owns 107,505,880 shares, accounting for about 20.61% of the total shares[169]. - A total of 28,125,000 options have been granted under the pre-IPO share option plan, representing approximately 5.40% of the issued share capital as of the report date[174]. - 21,775,000 shares, or about 4.17% of the issued share capital, have been exercised under the pre-IPO share option plan[174]. - 6,350,000 shares, or approximately 1.22% of the issued share capital, remain unexercised under the pre-IPO share option plan[174]. Stock Option Plan - The company adopted a share incentive plan on November 23, 2022, aimed at recognizing and rewarding contributions to the group's growth and development[153]. - The stock option plan was adopted on January 26, 2022, to align the interests of eligible participants with the company's goals[184]. - The maximum number of shares that can be issued under the stock option plan is capped at 10% of the total issued shares, equivalent to 50,000,000 shares[192]. - The exercise price for any shares under the stock option plan will not be less than the higher of the closing price on the grant date or the average closing price over the five trading days preceding the grant date[191]. - The stock options granted under the plan are non-transferable and cannot be sold or mortgaged by the grantee[196]. - The vesting schedule remains applicable even if the grantee's employment status changes[197]. - The board can decide on the forfeiture of unvested stock options at its discretion[199]. Management and Governance - The company’s board approved the interim financial statements on November 28, 2022, ensuring compliance with relevant accounting standards[155]. - The company has no significant events after the reporting period that would impact the financial statements[160]. - The group did not recognize any single customer contributing more than 10% of total revenue during the reporting period[100]. - The group has not experienced any impact from the early application of revised accounting standards on its financial position or performance[94][95][99].

Financial Performance - For the fiscal year ending March 31, 2022, Clarity Medical Group reported total revenue of HKD 225.2 million, a slight increase of 1.3% from HKD 222.4 million in the previous year[11]. - The net profit for the year was HKD 13.5 million, representing a significant decrease of 62.3% compared to HKD 35.8 million in the prior year[11]. - Adjusted net profit decreased by 21.7% to HKD 30.9 million from HKD 39.4 million year-over-year[11]. - The company's net profit margin fell to 6.0% from 16.1% in the previous year, indicating a decline in profitability[11]. - The adjusted net profit margin for the year was 13.7%, down from 17.7% in the previous year, reflecting challenges in maintaining profitability[11]. - Clarity Medical Group's financial performance indicates a need for strategic adjustments to enhance profitability and revenue growth moving forward[11]. Revenue Sources - Revenue from refractive surgery, the largest source of income, decreased by approximately HKD 9.1 million or 5.6% to about HKD 152.6 million for the year ended March 31, 2022[30]. - The number of SMILE surgeries performed decreased from 4,063 in the previous year to 3,802, leading to a revenue drop of approximately HKD 12.4 million or 12.4%[30]. - The average price for SMILE surgery decreased from HKD 24,600 to HKD 23,100, while LASIK surgery remained relatively stable[28]. - Revenue from other eye treatment services increased by approximately HKD 10.3 million, contributing to overall revenue growth[25]. - Revenue from other eye treatment increased from approximately HKD 44.8 million in 2021 to approximately HKD 55.1 million in 2022, representing a growth of 23.0%[32]. - Revenue from diagnostic and examination services rose from approximately HKD 9.1 million in 2021 to approximately HKD 10.2 million in 2022, an increase of 12.1%[33]. - Revenue from the sale of prescription drugs and others increased from approximately HKD 6.9 million in 2021 to approximately HKD 7.4 million in 2022, accounting for 3.1% and 3.3% of total revenue respectively[34]. IPO and Capital Allocation - Clarity Medical Group successfully completed its global offering, raising approximately HKD 181.9 million net of underwriting commissions and other expenses[13]. - The company achieved a significant milestone by listing on the Hong Kong Stock Exchange on February 18, 2022, marking its first annual report since the IPO[17]. - 44.8% of the IPO proceeds (approximately HKD 81.5 million) is allocated for establishing two new medical centers in Hong Kong[125]. - 30.5% of the IPO proceeds (approximately HKD 55.5 million) is designated for acquiring one to two ophthalmology clinics or hospitals in selected cities in the Greater Bay Area[125]. - 14.7% of the IPO proceeds (approximately HKD 26.7 million) is planned for setting up ophthalmology clinics in China with suitable partners[125]. - The total estimated allocation of IPO proceeds was HKD 245.6 million, which is higher than the actual net proceeds of HKD 181.9 million[125]. Cost and Expenses - Cost of used inventory increased from approximately HKD 37.0 million in 2021 to approximately HKD 38.5 million in 2022, representing 16.6% and 17.1% of total revenue respectively[38]. - Consultant fees rose from approximately HKD 55.8 million in 2021 to approximately HKD 63.0 million in 2022, accounting for 25.1% and 28.0% of total revenue respectively[39]. - Employee benefit expenses increased from approximately HKD 36.3 million in 2021 to approximately HKD 42.0 million in 2022, representing 16.3% and 18.7% of total revenue respectively[40]. - Other expenses increased from approximately HKD 20.3 million in 2021 to approximately HKD 24.2 million in 2022, accounting for 9.1% and 10.7% of total revenue respectively[44]. - Business development expenses increased by approximately HKD 1.2 million or 25.0% year-on-year, reaching approximately HKD 6.0 million in 2022[44]. Strategic Initiatives - The company is preparing to expand into the Greater Bay Area market, anticipating increased demand for quality ophthalmic services due to economic growth and favorable government policies[22]. - The company plans to leverage its extensive experience in the Hong Kong ophthalmic industry to gain a competitive advantage in the Greater Bay Area[22]. - The company aims to achieve sustainable growth and strengthen its position in the ophthalmic services market through the establishment of new medical centers and acquisitions in Hong Kong[69]. - Plans to acquire equity interests in ophthalmology clinics, outpatient departments, or hospitals in China to expand the "Clear" brand business[69]. - The company plans to identify suitable partners to establish ophthalmology clinics in China to provide ophthalmic medical services[69]. Governance and Management - The company has appointed independent non-executive directors with extensive experience in their respective fields, enhancing governance and oversight[93][97]. - The operational director has over 18 years of medical practice experience, including more than 10 years in ophthalmology, ensuring strong leadership in medical services[99][101]. - The company has established a robust governance structure with various committees to ensure effective management and compliance[96][100]. - The independent directors' roles include providing independent opinions to the board, which is essential for balanced decision-making[93][97]. - The management team emphasized the importance of digital transformation, aiming to increase online sales by 30% through enhanced e-commerce platforms[85]. Share Options and Equity - As of March 31, 2022, the total number of share options granted to directors and senior management was 26,687,500, with 5,530,000 options exercised[139]. - The company adopted a share option plan on January 26, 2022, aimed at aligning the interests of key talents with the company's goals[143]. - The maximum number of shares that can be issued under the share option plan is capped at 10% of the total issued shares as of the listing date, equivalent to 50,000,000 shares[151]. - The share option plan allows for the issuance of options to directors, employees, consultants, and business partners based on performance and tenure[146]. - The five largest customers contributed less than 1% to the total revenue, with no single customer contributing more than 0.2% for the fiscal year ending March 31, 2022[167]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[85]. - New product development includes the introduction of two innovative medical devices expected to generate an additional HKD 300 million in revenue[85]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 10% market share within the next three years[85]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's market position and increase overall revenue by 15%[85]. - The company has allocated HKD 100 million for research and development in the upcoming year to enhance product offerings and technological advancements[85].